XMT-2056 is a systemically-administered Immunosynthen STING agonist antibody drug conjugate (DAR 8) that is designed to target a novel HER2 epitope (distinct from pertuzumab and trastuzumab) and locally activate STING signaling in both tumor-resident immune cells and in tumor cells (a “one-two punch”), providing the potential to treat patients with HER2-high or -low tumors as monotherapy or in combination with standard-of-care HER2 agents.

A multicenter Phase 1 trial is underway to investigate the safety, tolerability and anti-tumor activity of XMT-2056 in patients with HER2-positive solid tumors, including in breast, gastric, colorectal and non-small-cell lung cancers. 

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to XMT-2056 for the treatment of gastric cancer.

For more information about our ongoing Phase 1 trial of XMT-2056, visit clinicaltrials.gov (NCT05514717).